Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
Trial details
- Registry ID
- NCT02014844
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as INNO-206
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaNCT02014844 | IBRX | Phase 2 | Completed | 2016-12Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |